Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly and Company

Next Previous
Drug Profile

Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly and Company

Alternative Names: 603281-31-8; LY-GSK-3i

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Azepines; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Apoprotein stimulants; Cell cycle modulators; Glycogen synthase kinase 3 inhibitors; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Muscular atrophy; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in USA
  • 20 Apr 2010 Pharmacodynamics data from preclinical trials in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research
  • 14 Dec 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top